pills-384846_960_720-300x200-4567758Industry lawsuits filed against Governor Cuomo’s $100 million opioid tax, summarized in today’s Wall Street Journal, are raising fresh questions about the levy’s fairness and unintended side effects.

In one suit, a subsidiary of drug manufacturer Mallinckrodt reports that it is being billed 8.2 cents per tablet for a form of Oxycodone that sold for 4.7 cents per tablet. Yet the law forbids companies from passing the cost of the tax along to buyers, effectively forcing Mallinckrodt to take a loss.

“Basic economic reality dictates that if a generic manufacturer is guaranteed to lose money on its sale or distribution of an opioid medication in New York, it will abandon the New York opioid market completely,” the company said in its suit, according to the Journal.

The article further reports that “some companies are re-engineering their supply chain to avoid the new tax.” Among them is drug distributor AmerisourceBergen:

AmerisourceBergen told Mallinckrodt on Oct. 10 that it will no longer accept opioid shipments at its national distribution center in Columbus, Ohio, that are intended for New York, according to Mallinckrodt’s lawsuit. If others follow, Mallinckrodt said, manufacturers will bear the entire cost of the surcharge. Under the law, distributors that send drugs into New York from a central hub outside the state get hit by the surcharge, not the pill maker.

The industry also argues that the tax could jeopardize the availability of certain drugs for New Yorkers who legitimately need them, and could prompt New York-based pharmaceutical companies to move out of the state.

As proposed by the governor and approved by the Legislature this year, the tax applies to all opioid pain relievers sold into New York, with the exception of products sold to hospice providers and drug rehab facilities. The amount to be raised is fixed at $100 million per year, which is allocated to each company in proportion to its volume of sales after adjusting for the strength of various products. The first round of bills, covering sales in 2017, were sent to 75 companies last week, the Journal reported.

The Cuomo administration originally justified the tax on two grounds – that it would raise money for the treatment and prevention of drug abuse, and that it would create a “financial disincentive” for the overuse of opioids.

However, there was no commensurate increase in spending on drug treatment, meaning most of the new revenue is replacing existing funds that are now available to be spent on other programs – in effect, helping to balance the overall state budget.

Also, the law says the cost of the tax cannot be passed along to buyers – such as hospitals, clinics, pharmacies, health plans and patients – which would seem to negate any deterrent effect on overuse.

In a statement to the Journal, a spokesman for the governor offered another rationale for the tax – that it “helps hold big pharma responsible for the opioid crisis they helped fuel.”

As the article pointed out, however, the state is also suing opioid manufacturers and distributors for their role in the crisis. The industry contends the tax is “an improper end-run around resolution of that case.”

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

Emails Confirm That Cuomo’s Staff Launched Its ‘Book’ Project in March 2020

A pair of state-employed writers began researching, outlining and drafting a book about Governor Andrew Cuomo's pandemic response in late March 2020, weeks before New York's harrowing first wave had passed, according to newly disclosed email records. Read More

NY school spending again led US, hitting all-time high in 2020-21

Public elementary and secondary school spending in New York rose to $26,571 per pupil in 2020-21, according to the latest Census Bureau data Read More

A Tale of Two Levies

New York school districts are getting record levels of state aid. But how many are using it to cut taxes? Read More

A Politically Active Medical Group Gains Access to Funds for ‘Distressed’ Providers

A politically connected medical group in the Bronx garnered an unusual benefit in the new state budget – access to money previously reserved for financially troubled safety-net hospitals and nursing homes. Read More

Budget deal increases state-share Medicaid spending by 13 percent

(This post has been updated to correct errors.) Albany's newly enacted budget appears to increase the state share of Medicaid spending by $4.2 billion or 13 percent, contin Read More

Albany’s Belated Budget Binge 

State lawmakers have begun passing the bills necessary to implement the state budget for the fiscal year that began April 1. Read More

Hochul’s ‘Pay and Resolve’ Push for Hospitals Triggers Déjà Vu

Two years ago last week, I wrote in the Daily News about how then-Governor Andrew Cuomo was pushing a costly change to insurance law on behalf of a hospital group that had supported his campaign through a fund-rai Read More

Courts set a limit on NY’s tax reach

Just in time for tax season, New York State's tax agency just lost a major legal challenge to its policy of pursuing maximum income tax payments from wealthy vacation homeowners—even when they live elsewhere. Read More

Empire Center Logo Enjoying our work? Sign up for email alerts on our latest news and research.
Together, we can make New York a better place to live and work!